insulin-producing stem-islet beta cell hybrids (Symbiocelltech)

N/A

Report date: 2025/05/15 20:00:08

Base Information

Drug Nameinsulin-producing stem-islet beta cell hybrids (Symbiocelltech)

Drug Alias Nameneo-islets (SymbioCellTech)

ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Source of cells > Adipose-derivedCell and gene therapy > Cell therapy > Stem cell therapy > Mesenchymal stem cells therapy

Mechanisms of ActionUpdating

TargetsUpdating

Therapy Area/IndicationsDiabetes Mellitus, Type 1

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesEgypt

CombinationsNo

Global Highest StatusPhase 3 Clinical

Highest Status in ChinaN/A

Originator CompaniesSymbioCellTech LLC

China Registration ClassN/A

Develop Information

Active CompaniesSymbioCellTech LLC Ain Shams University

Inactive CompaniesN/A

Active IndicationsDiabetes Mellitus, Type 1

Inactive IndicationsN/A

Other Information

ATC CodeN/A